In-silico Assessment of CYP2C19 and CYP3A4 Inhibitory Potential of Ilaprazole

CYP2C19 enzyme plays a crucial role in the metabolism of many drugs and PPIs are found to be potent inhibitors of CYP2C19, thereby affecting the clinical outcome of certain drugs that are administered concomitantly. Ilaprazole due to its pharmacokinetic variability may not have inhibitory effect on CYP450 isoforms. The current study aims to examine the inhibitory activity of ilaprazole to conventional PPIs using in-silico methodologies for cytochrome P450 3A4 and 2C19. We used Lipinski's rule of five to PPIs in this in-silico investigation, and we also assessed the ADMET characteristics of ligands. Additionally, docking studies were conducted for PPIs. Different targeted proteins were docked with each PPI (PDB IDs: 4D7D, 4GQS). Based on the docking findings, the current study found that ilaprazole inhibits the CYP3A4 and 2C19 enzymes, but to a lesser extent than other conventional PPIs. Proton pump inhibitors that show pharmacokinetic drug interactions mediated by these enzymes have poor therapeutic outcomes. In such cases, ilaprazole might be the suitable option among PPIs